Title:
PD-1に対する抗体分子およびその使用
Document Type and Number:
Japanese Patent JP2019503349
Kind Code:
A
Abstract:
PD−1に特異的に結合する抗体分子が開示される。該抗体分子は、癌または感染性状態および障害の処置または予防に使用され得る。
More Like This:
WO/2016/016412 | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
WO/2022/140321 | MAGE-B2-SPECIFIC T-CELL RECEPTORS |
WO/1996/031601 | POLYNUCLEOTIDE IMMUNOGENIC AGENTS |
Inventors:
Sanella Brick
Danny Roland Howard Jr.
John Scott Cameron
Glen Dranoff
Danny Roland Howard Jr.
John Scott Cameron
Glen Dranoff
Application Number:
JP2018531392A
Publication Date:
February 07, 2019
Filing Date:
December 16, 2016
Export Citation:
Assignee:
Novartis Age
International Classes:
C07K16/30; A61K31/337; A61K31/4045; A61K31/4439; A61K31/55; A61K39/395; A61K45/00; A61K45/06; A61P35/00; A61P35/02; A61P43/00; C12N15/13
Foreign References:
WO2015112900A1 | 2015-07-30 |
Other References:
J. ZHANG: "Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC", INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, JPN6019038636, 9 August 2015 (2015-08-09), ISSN: 0004206777
Attorney, Agent or Firm:
Michiko Matsutani
Kenji Tomita
Kenji Tomita